Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.


  1. Advanced Patent Search
Publication numberCA2208671 A1
Publication typeApplication
Application numberCA 2208671
PCT numberPCT/US1995/015384
Publication date11 Jul 1996
Filing date20 Nov 1995
Priority date30 Dec 1994
Also published asCA2208671C, DE69535195D1, DE69535195T2, EP0800514A1, EP0800514B1, US6429221, US6844359, US7329761, US20020143027, US20050090516, WO1996020926A1
Publication numberCA 2208671, CA 2208671 A1, CA 2208671A1, CA-A1-2208671, CA2208671 A1, CA2208671A1, PCT/1995/15384, PCT/US/1995/015384, PCT/US/1995/15384, PCT/US/95/015384, PCT/US/95/15384, PCT/US1995/015384, PCT/US1995/15384, PCT/US1995015384, PCT/US199515384, PCT/US95/015384, PCT/US95/15384, PCT/US95015384, PCT/US9515384
InventorsGeorge Muller, Mary Shire, David I. Stirling
ApplicantCelgene Corporation, George Muller, Mary Shire, David I. Stirling
Export CitationBiBTeX, EndNote, RefMan
External Links: CIPO, Espacenet
Substituted imides as tnf inhibitors
CA 2208671 A1
Novel imides of the general formula (see above formula) are inhibitors of tumor necrosis factor alpha and can be used to combat cachexia, endotoxic shock, and retrovirus replication. A typical embodiment is 2-Phthalimido-3-(3',4'-dimethoxyphenyl)propane.
Description  available in
Claims  available in
International ClassificationA61K31/40, A61K31/403, A61P9/00, A61K31/4035, A61P37/00, C07D209/46, A61P1/00, C07D209/48, A61P43/00, A61P29/00, A61P31/00
Cooperative ClassificationC07D209/46, C07D209/48
European ClassificationC07D209/46, C07D209/48
Legal Events
21 Oct 2002EEERExamination request
21 Nov 2011MKLALapsed